Author:
Pérez Alonso Laura,Cervera Calero Raquel,Campos Fernández de Sevilla María Ángeles,Moreno Palanco Miguel Ángel,Gómez Cerezo Jorge Francisco
Reference8 articles.
1. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease;Sabatine;N Engl J Med.,2017
2. Agencia española de Medicamentos y Productos Sanitarios. Informe de posicionamiento terapéutico de lorlatinib (Lorviqua®)en cancer de pulmón no microcítico ALK positivo [consultado 2 Dic 2022]. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/2021/IPT_6-2021-Lorviqua.pdf
3. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol.,2018
4. Lorlatinib as a treatment for ALK-positive lung cancer;Baba;Future Oncol.,2022
5. Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners;Reed;Adv Ther.,2020